Document is current
Any future updates will be listed below
-
Authors
Grohmann, Christoph
Magtoto, Charlene M.
Walker, Joel R.
Chua, Ngee Kiat
Gabrielyan, Anna
Hall, Mary
Cobbold, Simon A.
Mieruszynski, Stephen
Brzozowski, Martin
Simpson, Daniel S.
Dong, Hao
Dorizzi, Bridget https://orcid.org/0000-0002-7557-5445
Jacobsen, Annette V. https://orcid.org/0000-0003-0252-7685
Morrish, Emma
Silke, Natasha
Murphy, James M. https://orcid.org/0000-0003-0195-3949
Heath, Joan K. https://orcid.org/0000-0001-6955-232X
Testa, Andrea https://orcid.org/0000-0002-8973-9711
Maniaci, Chiara https://orcid.org/0000-0001-7887-7388
Ciulli, Alessio https://orcid.org/0000-0002-8654-1670
Lessene, Guillaume https://orcid.org/0000-0002-1193-8147
Silke, John https://orcid.org/0000-0002-7611-5774
Feltham, Rebecca https://orcid.org/0000-0001-8376-6869
- License Information
-
More Information
Article History
Received: 22 April 2021
Accepted: 25 March 2022
First Online: 19 April 2022
Competing interests
: The A.C. Laboratory has received sponsored research support from Almirall, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Nurix Therapeutics, and Ono Pharmaceutical. A.C. is a scientific founder, shareholder and consultant of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. J.R.W. is an employee of Promega corporation. The remaining authors declare no competing interests.
